Based on Cripto-1 expression and serum AFP values, HCC patients were categorized into four groups with different recurrent risks and prognosis: group I with Cripto-1 (−) and AFP ≤ 400 ng/mL, good prognosis and low-risk of recurrence; group II with Cripto-1 (−) and AFP > 400 ng/mL, and group III with Cripto-1 (+) and AFP ≤ 400 ng/mL, intermediate prognosis and intermediate-risk of recurrence; group IV, Cripto-1 (+) and AFP > 400 ng/mL, poor prognosis and high-risk of recurrence (Figure 5). This evidence concerns the gene CRIPTO and hepatocellular carcinoma.